Table 2.
Clinical studies investigating the role of NLR in predicting cancer patient outcomes.
| Reference | Cancer type | Measurements | # of patients | Range cutoffs | Multivariate HR (OS) | Time of measurement |
|---|---|---|---|---|---|---|
| Absenger et al. (17) | Colon | NLR | 504 | NLR > 4 | 1.95, p = 0.006 | Preoperative |
| Azab et al. (75) | Breast | NLR | 316 | NLR > 3.3 | 4.07, p = 0.002 | Pretreatment |
| Jung et al. (76) | Gastric | NLR | 293 | NLR > 2.0 | 1.61, p = 0.006 | Presurgery |
| Pichler et al. (128) | Renal cell carcinoma | NLR | 678 | NLR > 3.3 | 1.59, p = 0.014 CSS—1.39, p = 0.184 |
Pretreatment |
| Proctor et al. (50) | Multiple | NLR dNLR |
12,118 | NLR > 4dNLR > 2 | Prediagnosis—NLR—1.57, p < 0.001, dNLR—1.54, p < 0.001 Postdiagnosis—NLR—1.86, p < 0.001, dNLR—1.76, p < 0.001 |
Within 2 years of diagnosis |
| Rachidi et al. (77) | Head and neck | NLR | 543 | NLR in highest tertile | 2.39, p = 0.0001 | Pretreatment |
| Ubukata et al. (78) | Gastric | NLR | 157 | NLR > 5 | RR—5.78, p < 0.001 (presurgery) RR—3.26, p = 0.540 (postsurgery) |
Presurgery and 14 days post |
| Viers et al. (79) | Clear cell carcinoma | NLR | 827 | NLR > 4 | 1.02, p < 0.01 | Pretreatment |
CSS, cancer-specific survival; OS, overall survival; RR, relative risk.